Comparing the effect of Alpha blocker (Silodosin) and Phosphodiesterase type 5 inhibitor (Tadalafil) in benign prostate hyperplasia patients with lower urinary tract symptoms: a single centre study

Authors

  • Sanket Narayan Singh Department of Surgery, Himalayan Institute of Medical Sciences, Dehradun, Uttarakhand, India
  • Manoj Biswas Department of Urology, Himalayan Institute of Medical Sciences, Dehradun, Uttarakhand, India
  • Ankur Mittal Department of Urology, Himalayan Institute of Medical Sciences, Dehradun, Uttarakhand, India
  • Yogesh Kalra Department of Urology, Himalayan Institute of Medical Sciences, Dehradun, Uttarakhand, India
  • Rajeev Sarpal Department of Urology, Himalayan Institute of Medical Sciences, Dehradun, Uttarakhand, India
  • Shikhar Agrawal Department of Urology, Himalayan Institute of Medical Sciences, Dehradun, Uttarakhand, India
  • Ravinder Pal Department of Surgery, Himalayan Institute of Medical Sciences, Dehradun, Uttarakhand, India
  • Bhavishya Chugh Department of Surgery, Himalayan Institute of Medical Sciences, Dehradun, Uttarakhand, India

DOI:

https://doi.org/10.18203/2349-2902.isj20181599

Keywords:

Alpha blockers, Benign prostatic hyperplasia, Lower urinary tract symptoms, Phosphodiesterase 5 inhibitors

Abstract

Background: Benign prostatic hyperplasia (BPH) is a histologic diagnosis that refers to the proliferation of smooth muscle and epithelial cells within the prostatic transition zone. The aim of this systematic review is to determine the comparative effectiveness and safety of phosphodiesterase 5 inhibitors (PDE5-Is) and alpha blockers used alone or in combination for the treatment of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH).

Methods: We analyzed 54 patients of BPH with LUTS with baseline IPSS, Qmax and PVR over one-year period. They were randomized equally in three groups i.e. group receiving alpha blocker, group receiving phosphodiesterase 5 inhibitors and group receiving combination of the two drugs. These patients were followed up at the end of 1st month and 3rd month and IPSS, Qmax and PVR was compared.

Results: Out of 54, 45 patients completed the study. At the end of the study all the three groups showed significant improvement in IPSS, PVR and Qmax, all p <0.05, but the combination group showed much better improvement in terms of percentage. Two patients on alpha blockers had episode of hypotension.

Conclusions:Thus, we summarize that phosphodiesterase 5 inhibitors should be preferred over alpha blockers in patients with LUTS/BPH as it has, firstly, outcome similar to alpha blockers. Secondly, have no documented side effect. Third, can be given in any patient, irrespective of the fact that whether the patient is suffering from erectile dysfunction or not. 

 

References

Lee C, Kozlowski J, Grayhack J. Intrinsic and extrinsic factors controlling benign prostatic growth. Prostate. 1997;31:131-9.

Auffenberg G, Helfan B, McVary K. Established medical therapy for benign prostatic hyperplasia. Urol Clin North Am. 2009;36:443.

Reynard JM. Does anticholinergic medication have a role for men with lower urinary tract symptoms/benign prostatic hyperplasia either alone or in combination with other agents? Curr Opin Urol. 2004;14:13-20.

Price DT, Schwinn DA, Lomasney JW, Allen LF, Caron MG, Lefkowitz RJ. Identification, quantification, and localization of mRNA for three distinct alpha A1 adrenergic receptor subtypes in human prostate. J Urol. 1993;150:546-51.

Kojima Y, Sasaki S, Shinoura H, Hayashi Y, Tsujimoto G, Kohri K. Quantification of alpha1-adrenoceptor subtypes by real-time RT PCR and correlation with age and prostate volume in benign prostatic hyperplasia patients. Prostate. 2006;66:761-67.

Kojima Y, Sasaki S, Kubota Y. Expression of alpha1-adrenoceptor subtypem RNA as a predictor of the efficacy of subtype selective alpha1-adrenoceptor antagonists in the management of benign prostatic hyperplasia. J Urol. 2008;179:1040-6.

Montorsi F. Profile of Silodosin. Eur Urol Suppl. 2010;9:491-5.

Shibata K, Foglar R, Horie K. KMD-3213, a novel, potent, a1A-adrenoceptor-selective antagonist: characterization using recombinant human a1-adrenoceptors and native tissues. Mol Pharmacol. 1995;48:250-8.

Takei R, Ikegaki I, Shibata K, Tsujimoto G, Naftopidil AT. A novel a1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human a1-adrenoceptors. Jpn J Pharmacol. 1999;79:447-54.

Shibata K, Foglar R. KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues. Molecular Pharmacol. 1995;48(2):250-8.

Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol. 2009;181(6):2634-40.

Angulo J, Cuevas P, Fernandez A. Tadalafil enhances the inhibitory effects of tamsulosin on neurogenic contractions of human prostate and bladder neck. J Sex Med. 2012;9:2293-306.

McVary KT, Roehrborn CG, Kaminetsky JC. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2007;177:1401-7.

Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol. 2008;180:1228-34.

Marberger M. The MTOPS study: new findings, new insights, and clinical implications for the management of BPH. Eu Urol. 2006;5:628-33.

Roehrborn CG, Siami P, Barkin J, Damiao R, Major-Walker K, Nandy I, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the combat study. Eu Urol. 2010;57(1):123-31.

Gratzke C, Bachmann A, Descazeaud A, Drake MJ, Madersbacher S, Mamoulakis C. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2015;67:1099-109.

Afonso AS, Verhamme KM, Stricker BH, Sturkenboom MC, Brusselle GG. Inhaled anticholinergic drugs and risk of acute urinary retention. BJU Int. 2011;107:1265-72.

Moon KH, Song PH, Yang DY, Park NC. Efficacy and safety of the selective α1A-adrenoceptor blocker Silodosin for severe lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective, single-open-label, multicenter study in Korea. Korean J Urol. 2014;55:335-40.

Lee SW, Paick JS, Park HJ, Won E, Morisaki Y. The efficacy and safety of Tadalafil 5 mg once daily in Korean men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: an integrated analysis. World J Mens Health. 2014;32(1):28-35.

Lee JY, Park SY, Jeong TY. Combined Tadalafil and a-Blocker therapy for benign prostatic hyperplasia in patients with erectile dysfunction: a multicenter, prospective study. J Androl. 2012;33(3):21-7.

Yoshida T, Kinoshita H, Shimada S, Taguchi M, Matsuda T. Comparison of Silodosin monotherapy vs Silodosin with Tadalafil add-on therapy in patients with benign prostatic hyperplasia. Urol. 2017;106:153-9.

Wang XH, Wang X, Shi MJ, Li S, Liu T, Zhang XH. Systematic review and meta-analysis on phosphodiesterase 5 inhibitors and α-adrenoceptor antagonists used alone or combined for treatment of LUTS due to BPH. Asian J Androl. 2015;17(6):1022-32.

Brock G, Broderick G, Roehrborn CG, Xu L, Wong D. Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction. BJU Int. 2013;112:990-7.

Cho HJ, Yoo TK. Silodosin for the treatment of clinical benign prostatic hyperplasia: safety, efficacy, and patient acceptability. Res Rep Urol. 2014;6:113-9.

Downloads

Published

2018-04-21

Issue

Vol. 5 No. 5 (2018): May 2018

Section

Original Research Articles